Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136224 | 0.92 | KMT2A (0.73) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL13834441 | 0.88 | KMT2A (0.68) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL1605914 | 0.85 | MEN1 (0.53) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL31732466 | 0.85 | MEN1 (0.53) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL19420470 | 0.85 | EPHX2 (0.53) | MEN1MAPK1KMT2AEPHX2HDAC1 | |
| SCHEMBL8294972 | 0.84 | MEN1 (0.49) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL22796049 | 0.84 | MEN1 (0.58) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL19420468 | 0.84 | MEN1 (0.58) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL1497414 | 0.84 | MEN1 (0.58) | MEN1MAPK1KMT2AEPHX2CACNA1H | |
| SCHEMBL20940142 | 0.83 | MEN1 (0.50) | MEN1MAPK1KMT2AEPHX2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025016323-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | MEN1 2821/4885MAPK1 1860/4885KMT2A 171/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | MEN1 3264/4885MAPK1 884/4885KMT2A 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.